Veritas In Silico Inc. (TYO:130A)
Japan · Delayed Price · Currency is JPY 644.00
+3.00 (0.47%)
Last updated: Jul 25, 2025
Veritas In Silico Company Description
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA.
It has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development.
The company was incorporated in 2016 and is based in Shinagawa, Japan.
Veritas In Silico Inc.
| Country | Japan |
| Founded | 2016 |
| Industry | Surgical and Medical Instruments and Apparatus |
| CEO | Shingo Nakamura |
Contact Details
Address: 1-11-1 Nishigotanda Shinagawa, 141-0031 Japan | |
| Website | veritasinsilico.com |
Stock Details
| Ticker Symbol | 130A |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Shingo Nakamura | Chief Executive Officer |
| Hiroyuki Matsuoka | Chief Financial Officer |
| Takashi Kamimura | Chief Operating Officer |